Page 4 - Revascularization Device News Today

Penumbra, Inc. (NYSE:PEN – Get Free Report) EVP Johanna Roberts sold 600 shares of the business’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $249.85, for a total value of $149,910.00. Following the completion of the sale, the executive vice president now directly owns 64,837 shares […]

Integral Health Asset Management LLC increased its holdings in shares of Penumbra, Inc. (NYSE:PEN – Free Report) by 16.7% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 35,000 shares of the company’s stock after acquiring an additional 5,000 shares during the period. Penumbra makes […]

Integral Health Asset Management LLC raised its position in Penumbra, Inc. (NYSE:PEN – Free Report) by 16.7% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 35,000 shares of the company’s stock after acquiring an additional 5,000 shares during the period. Penumbra makes up about 2.0% of Integral […]

Arcadia Investment Management Corp MI lifted its stake in Penumbra, Inc. (NYSE:PEN – Free Report) by 131.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 312 shares of the company’s stock after buying an additional 177 shares during the period. Arcadia Investment […]

Penumbra (NYSE:PEN – Get Free Report) posted its earnings results on Tuesday. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.15, Briefing.com reports. The company had revenue of $261.50 million for the quarter, compared to the consensus estimate of $253.59 million. Penumbra had a return on equity of […]

Penumbra (NYSE:PEN – Free Report) had its target price lifted by Wells Fargo & Company from $320.00 to $337.00 in a research note released on Wednesday, Marketbeat.com reports. The brokerage currently has an overweight rating on the stock. Several other analysts have also commented on the stock. Deutsche Bank Aktiengesellschaft increased their target price on […]

Penumbra (NYSE:PEN – Free Report) had its target price cut by Truist Financial from $370.00 to $345.00 in a research report report published on Wednesday morning, MarketBeat reports. They currently have a buy rating on the stock. Several other equities analysts also recently weighed in on PEN. Citigroup raised their price objective on Penumbra from […]

Penumbra (NYSE:PEN – Get Free Report) had its target price lowered by analysts at Canaccord Genuity Group from $351.00 to $322.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price suggests a potential upside of 19.50% […]

Penumbra (NYSE:PEN – Get Free Report) will be posting its quarterly earnings results after the market closes on Tuesday, August 1st. Analysts expect Penumbra to post earnings of $0.28 per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link. Penumbra (NYSE:PEN – Get Free […]

Penumbra (NYSE:PEN – Get Free Report) and H-CYTE (OTCMKTS:HCYTD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation. Insider and Institutional Ownership 91.1% of Penumbra shares are held […]